Health Promotion and Disease Prevention Sample Clauses

Health Promotion and Disease Prevention. 1.4  Advises patients about the advantages of healthy lifestyles and specific measures that may prevent recurrences of ill health.  Participates in health promotion awareness campaigns relevant to her/ his speciality and the goals of MidCentral Health.
Sample 1Sample 2
Health Promotion and Disease Prevention. As part of the primary health care, UTMB will provide health promotion services as an important and required component of the total health care delivery system. Health
Sample 1Sample 2
Health Promotion and Disease Prevention. 2 term unit 520. PRINCIPLES OF PHYSICAL DIAGNOSIS-I – 3 term units 521. PRINCIPLES OF PHYSICAL DIAGNOSIS-II – 3 term units 522. PRINCIPLES OF PHYSICAL DIAGNOSIS-III – 3 term units 526. CLINICAL PHARMACOLOGY-I – 2 term units 527. CLINICAL PHARMACOLOGY-II – 2 term units 528. CLINICAL MEDICINE-I – 3 term units 529. CLINICAL MEDICINE-II – 4 term units 530. CLINICAL MEDICINE-III – 4 term units
Sample 1
Health Promotion and Disease Prevention. We may use your health information to tell you about disease prevention and healthcare options.
Sample 1
Health Promotion and Disease Prevention. For many clients the family planning program services are their only continuing source of health information and medical care. The Contractor may whenever possible, provide health maintenance services such as screening, immunization, and general health education and counseling directed toward health promotion and disease prevention. These additional services enhance the client’s general state of health, and in turn, the health of their families and children. Programs are therefore encouraged to assess the health problems prevalent among the populations they serve, and to develop services or referral mechanisms to address them.
Sample 1

Related to Health Promotion and Disease Prevention

  • Investigation and Prevention DST shall reasonably assist Fund in investigating of any such unauthorized access and shall use commercially reasonable efforts to: (A) cooperate with Fund in its efforts to comply with statutory notice or other legal obligations applicable to Fund or its clients arising out of unauthorized access and to seek injunctive or other equitable relief; (B) cooperate with Fund in litigation and investigations against third parties reasonably necessary to protect its proprietary rights; and (C) take reasonable actions necessary to mitigate loss from any such authorized access.

  • Infectious Diseases The Employer and the Union desire to arrest the spread of infectious diseases in the nursing home. To achieve this objective, the Joint Health and Safety Committee may review and offer input into infection control programs and protocols including surveillance, outbreak control, isolation, precautions, worker education and training, and personal protective equipment. The Employer will provide training and ongoing education in communicable disease recognition, use of personal protective equipment, decontamination of equipment, and disposal of hazardous waste.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the “FDA”) or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.